# Sotatercept (ACE-011) With Lenalidomide or Pomalidomide and Dexamethasone in Relapsed/Refractory Multiple Myeloma

> **NCT01562405** · PHASE1 · ACTIVE_NOT_RECRUITING · sponsor: **Massachusetts General Hospital** · enrollment: 33 (actual)

## Conditions studied

- Multiple Myeloma

## Interventions

- **DRUG:** ACE-011
- **DRUG:** Lenalidomide
- **DRUG:** Dexamethasone
- **DRUG:** Pomalidomide

## Key facts

- **NCT ID:** NCT01562405
- **Lead sponsor:** Massachusetts General Hospital
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2012-05
- **Primary completion:** 2026-12
- **Final completion:** 2027-12
- **Target enrollment:** 33 (ACTUAL)
- **Last updated:** 2026-01-14

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01562405

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01562405, "Sotatercept (ACE-011) With Lenalidomide or Pomalidomide and Dexamethasone in Relapsed/Refractory Multiple Myeloma". Retrieved via AI Analytics 2026-06-05 from https://api.ai-analytics.org/clinical/NCT01562405. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*